BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 21 June, 2007 Biotie Therapies Corp. announced that the June 22nd issue of"Alcoholism: Clinical and Experimental Research", a leading journal in addiction therapies, features a scientific article on nalmefene in the treatment of patients with alcohol problems. The featured study describes the results of the company's phase III clinical study that was conducted in Finland and enrolled about 400 patients with impaired control over their alcohol drinking. According to the results, targeted use of nalmefene during the 28 weeks of treatment decreased heavy drinking statistically significantly. The reduction in the number of heavy drinking days compared to placebo was about 32%. The company has communicated the main results of this study first in 2003. Turku, June 21, 2007 Biotie Therapies Corp. Timo Veromaa President and CEO For further information, please contact: Timo Veromaa, President and CEO, Biotie Therapies Corp. tel. +358 2 274 8901, e-mail: timo.veromaa@biotie.com www.biotie.com Distribution: Helsinki Stock Exchange Main Media